Seoul, South Korea

Kunhee Kim

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Korea Institute of Science and Technology. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0


 

Average Co-Inventor Count = 23.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kunhee Kim: Innovator in Hydrazone Derivatives

Introduction

Kunhee Kim is a notable inventor based in South Korea. He has made significant contributions to the field of chemistry, particularly in the development of novel hydrazone derivatives. His work focuses on the substitution of terminal amine groups with aryl or heteroaryl groups, which has potential applications in various industries.

Latest Patents

Kunhee Kim holds a patent titled "Novel Hydrazone Derivative In Which Terminal Amine Group Is Substituted With Aryl Group Or Heteroaryl Group, And Use Thereof." This invention relates to innovative hydrazone derivatives that can be utilized in multiple applications, showcasing his expertise in chemical compounds.

Career Highlights

He is currently affiliated with the Korea Institute of Science and Technology, where he continues to advance his research and development efforts. His work has contributed to the understanding and application of hydrazone derivatives in scientific research.

Collaborations

Kunhee Kim has collaborated with esteemed colleagues, including Ae Nim Pae and Yun Kyung Kim. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Kunhee Kim is a dedicated inventor whose work in hydrazone derivatives exemplifies the intersection of chemistry and innovation. His contributions to the field are noteworthy and continue to influence research and development in this area.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…